Edwards Lifesciences Corporation $EW Shares Sold by Robbins Farley

Robbins Farley cut its stake in Edwards Lifesciences Corporation (NYSE:EW) by 1.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 27,954 shares of the medical research company’s stock after selling 391 shares during the quarter. Robbins Farley’s holdings in Edwards Lifesciences were worth $2,186,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Jennison Associates LLC increased its position in shares of Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock worth $731,036,000 after purchasing an additional 2,576,383 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Edwards Lifesciences by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock valued at $491,673,000 after buying an additional 264,311 shares during the period. Nuveen LLC purchased a new stake in Edwards Lifesciences in the 1st quarter valued at about $330,881,000. Invesco Ltd. raised its holdings in Edwards Lifesciences by 2.6% in the 1st quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock valued at $310,773,000 after buying an additional 107,241 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Edwards Lifesciences by 5.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock valued at $287,140,000 after buying an additional 198,882 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

NYSE EW opened at $77.25 on Tuesday. The company has a market cap of $45.35 billion, a P/E ratio of 11.11, a P/E/G ratio of 3.67 and a beta of 1.07. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The stock has a 50-day moving average of $78.51 and a two-hundred day moving average of $75.83. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on EW. William Blair upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. Stifel Nicolaus set a $85.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a report on Monday, September 22nd. BTIG Research upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Tuesday, July 29th. Argus upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a report on Thursday, July 10th. Finally, Canaccord Genuity Group lifted their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a research report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $86.61.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares of the company’s stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.34% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.